RusnanoMedInvest
Venture capital company
RMI LLC was created by RUSNANO JSC in 2012 for the international investment in innovative projects in Life Sciences (medicine)
About us
We are investing
In the development of innovative medicines
We support companies developing new, promising products in the field of pharma and medical equiptment
Portfolio
International cooperation
RMI implemented an agreement between recognized technology investors
In 2012, Rusnano (Russia) and Domain Associates (USA) have concluded a strategic partnership agreement on joint investment in pharma and medical eqiupment for the development of innovations
The Agreement
RusnanoMedInvest
The aims
The RMI project is aimed at creation of the Russian world-level expertise in the field of veture investment in Life Sciences (medicine), as well as at the development of innovative pharmaceutical project - NovaMedica LLC (Russia)
NewsRusnanoMedInvest (RMI) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology
RMI was created in March 2012. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government.
The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia. The main objectives of RMI are:
- localization of innovative life sciences and pharmaceutical technology in Russia;
- creation and accumulation of Russian-originated world-class expertise in the field of venture capital financing in Life Sciences;
- stimulating the interest of investors and potential investors in the financing of Russian life sciences ideas, concepts and technologies.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.